Skip to content

Clinical and Ecological Impact of a Primary Care Antimicrobial Stewardship Program Based on Telematic Educational Interviews (TELÉMACO Trial)

Clinical and Ecological Impact of a Primary Care Antimicrobial Stewardship Program Based on Telematic Educational Interviews. A Cluster Randomized Clinical Trial (TELÉMACO Trial)

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06706583
Acronym
TELÉMACO
Enrollment
30
Registered
2024-11-26
Start date
2024-12-01
Completion date
2026-03-31
Last updated
2024-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Community Acquired Infections

Keywords

Antimicrobial Stewardship Program (ASP), Primary Care, Telemedicine, PIRASOA

Brief summary

Brief Summary: Open-label, cluster randomized, multicenter clinical trial to evaluate the clinical and ecological impact of a Primary Care ASP based on telematic educational interviews.

Detailed description

The objective of this project is to measure the effect of an Antimicrobial Stewardship Program (ASP) in Primary Care, based on an educational intervention. This will consist of periodic structured telematic educational interviews between Infectious Diseases experts and Family Medicine and paediatrics specialists. In these interviews, the principles for the optimal use of antimicrobials will be addressed on real cases, analyzing together prescriptions randomly chosen from the Primary Care physician himself. The repetition over time of key pedagogical messages for the optimisation of prescriptions is expected to improve the quality of antibiotic use, reduce the overall consumption, improve the use of microbiological tests, reduce the incidence of community infections caused by resistant microorganisms, and preserve patients' safety measured by the rate of admission for serious infections. The results derived from these educational interventions, in the framework of a multimodal ASP, have been evaluated in hospital and Primary Care settings in quasi-experimental studies with a favourable outcome, but not in a clinical trial that specifically assesses the efficacy of educational interviews and avoids the bias of uncontrolled studies. To demonstrate this hypothesis, a cluster randomized trial has been designed, in wich all healthcare centers will be assigned either to a control group (the standard measures defined by the regional ASP PIRASOA will be maintained), and an experimental group (whose physicians will receive the educational intervention described).

Interventions

BEHAVIORALTelematic educational interviews + standard training

Physicians attending at healthcare centers in the experimental arm will receive periodic telematic educational interviews in which an Infectious Diseases consultant will provide practical training on the appropriate use of antibiotics through the review of one of the physician´s randomly chosen antibiotic prescription, according to a structured brief interview. In addition to this, each of these centres will continue carrying out the already established activities of the Regional ASP (PIRASOA).

Primary Care Health Centers assigned to the control group will receive standard educational activities designated by the current Regional ASP (PIRASOA).

Sponsors

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Intervention model description

Cluster randomized clinical trial

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

a) Primary Care centres within the reference area of the University Hospital Virgen del Rocío.

Exclusion criteria

1. Emergency departments. 2. Odontology offices. 3. DDD per Health centre less than 5.78

Design outcomes

Primary

MeasureTime frameDescription
Total antimicrobial consumptionMonthly over a 36-month periodTotal antimicrobial antimicrobial will be measured using the recommended international standard, the Defined Daily Dose (DDD) per 1000 inhabitants per day. Predefined subgroup analyses will be conducted to assess the intervention's effect on the primary outcome based on: patient age, geneder, and socioeconomic level.

Secondary

MeasureTime frameDescription
Adequacy of antimicrobial prescriptionsPrevalence surveys will be performed at months +0, +7 and +15.The rate of appropriate antimicrobial prescriptions according to national reference guidelines will be assessed through three point prevalence surveys of randomly selected prescriptions.
Incidence density of hospitalizations due to infectionsMonthly, over a 36-month period.The incidence density of hospitalizations due to infections (urinary, pneumonia and skin and soft tissue infections), and specifically due to Clostridiodes difficile infections per inhabitant.
Incidence density of resistant Enterobacterales in urine culturesMonthly, over a 36-month period.Incidence density of resistant Enterobacterales in urine cultures per inhabitant sent from Primary Care centers from both arms.

Countries

Spain

Contacts

Primary ContactClara M Rosso Fernández, MD-PhD
claram.rosso.sspa@juntadeandalucia.es+34955013414
Backup ContactJose Molina Gil-Bermejo, MD-PhD
josemolinagb@gmail.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026